Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Liabilities and Shareholders Equity of $61.5 million for Q4 2025, down 10.38% year-over-year from $68.7 million in Q4 2024, and down 11.79% quarter-over-quarter from $69.8 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $61.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 10.38% year-over-year to $61.5 million; the TTM figure through Dec 2025 stood at $269.4 million (changed N/A YoY), while the FY2025 annual figure was $61.5 million, down 8.93% from the prior year.
- Liabilities and Shareholders Equity declined to $61.5 million in Q4 2025 per ZYBT's latest filing, from $69.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $69.8 million in Q2 2025 and bottomed at $61.5 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $67.4 million across 3 years, with a median of $69.0 million in 2024.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 1.1% — and 2025, when it dropped 10.38%.
- Zhengye Biotechnology Holding's Liabilities and Shareholders Equity stood at $69.4 million in 2023, then slipped by 1.1% to $68.7 million in 2024, then fell by 10.38% to $61.5 million in 2025.
- Business Quant data shows ZYBT's Liabilities and Shareholders Equity at $61.5 million in Q4 2025, $69.8 million in Q2 2025, and $68.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Zhengye Biotechnology Holding | 86.79 Mn | 79.48 Mn | - | 61.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61.54 Mn |
| Jun 30, 2025 | 69.77 Mn |
| Dec 31, 2024 | 68.67 Mn |
| Dec 31, 2023 | 69.43 Mn |